Add-on Acquisition • Life Science

Leap Therapeutics Acquires MacroCure

On August 29, 2016, Leap Therapeutics acquired life science company MacroCure

Acquisition Context

This is Leap Therapeutics’ 1st transaction in the Life Science sector.
This is Leap Therapeutics’ 1st transaction in Israel.

Explore All 3109 Add-on Acquisition Life Science Deals - Search the Database Free

M&A Deal Summary
Date	August 29, 2016
Target	MacroCure
Sector	Life Science
Buyer(s)	Leap Therapeutics
Deal Type	Add-on Acquisition
Advisor(s)	Raymond James - Investment Banking (Financial)

Target Company

MacroCure

Kiryat Matalon, Petach Tikva, Israel

MacroCure Ltd. is a biotechnology company focused on the development and commercialization of advanced cell therapy products. MacroCure currently manufactures and markets its lead product, CureXcell™, in Israel for difficult-to-heal wound treatment. MacroCure plans to begin a multinational Phase III study under an SPA, in the US, Canada and Israel in the second quarter 2011, for lower extremity ulcers in diabetic patients.

Explore More Deals

Browse All 215,130 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer

Leap Therapeutics

Cambridge, Massachusetts, United States

Category	Company
Sector	Life Science

DESCRIPTION

Leap Therapeutics, Inc. is an immuno-oncology company with two clinical stage programs. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein.

Deal Context for Buyer	#
Overall	1 of 1
Sector: Life Science	1 of 1
Type: Add-on Acquisition	1 of 1
Country: Israel	1 of 1
Year: 2016	1 of 1

Explore Related M&A Activity

Life Science M&A - Add-on Acquisition M&A Deals - Israel M&A - 2016 M&A